Greetings from Editorial Office of Translational Lung Cancer Research(TLCR).
In the past one year, the citation of TLCR Publication has increased by 644 times (from 277 times cited in January 2016 to 921 times cited in December 2016). Here we would like to extend our heartfelt appreciation to our Editorial Team, Editorial Board Members, Guest Editors, Authors, Reviewers and Readers whose contribution is indispensable to the progress of the journal.
More focused issues guest-edited by outstanding experts from the filed of Lung Cancer and related thoracic diseases will come in 2017. Let's work together to embrace the boom of TLCR in 2017!
11. Most Cited Articles in 2016
| Article Title | Authors |
| Targeted therapy for nonsmall cell lung cancer: Current standards and the promise of the future (Times Cited:32 ) | Brett G.M. Hughes et.al |
| Global trends of lung cancer mortality and smoking prevalence (Times Cited:27 ) | Farhad Islami et.al |
| Lung cancer molecular epidemiology in China: recent trends (Times Cited:21) | Caicun Zhou |
| Phosphatidylinositol 3kinaseAKT mammalian target of rapamycin (PI3KAktmTOR) signaling pathway in nonsmall cell lung cancer (Times Cited:20) | Po Yee Yip |
Note: Data were collected from Web of KnowledgeTM core collection (Dec 30,2016).
11. Most Cited Articles in 2016
| Article Title | Authors |
| Immune checkpoint inhibitors in clinical practice: update on management of immunerelated toxicities (Times Cited:20) | Brett G.M. Hughes et.al |
| ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it (Times Cited:19) | Farhad Islami et.al |
| Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutationsa review (Times Cited:18) | Caicun Zhou |
| Advances on EGFR mutation for lung cancer (Times Cited:18) | Po Yee Yip |
| Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer (Times Cited:16) | Po Yee Yip |
Note: Data were collected from Web of KnowledgeTM core collection (Dec 30,2016).
